USOR 23328 - STAR Ph2 study of BI 1810631 for the treatment of HER-2 mutated solid tumors

Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours (1479-0009)

Disease Types: Solid Tumor

Available at: Arlington Heights, Niles